Trials in set up
CAPTIVATE
Diet-driven gut microbiome and outcome in patients with early-stage triple-negative breast cancer undergoing neoadjuvant chemotherapy and immunotherapy
Open to recruitment
DIAMOND
An open-label randomised, phase II trial of Datopotamab deruxtecan plus Durvalumab versus Datopotamab deruxtecan in patients with PDL1-negative metastatic Triple-Negative Breast Cancer
DISCUS
A randomised phase II study comparing 3 vs 6 cycles of platinum-based chemotherapy prior to maintenance avelumab in advanced urothelial cancer.
CARE-1
First line Randomised study platform to optimize treatment in patients with metastatic renal cell carcinoma
In follow up (closed to recruitment)
STARPAC2
Phase IIb randomised clinical trial repurposing ATRA as a stromal targeting agent in a novel drug combination for pancreatic cancer.
PAKT
A Phase II, Double Blind, Randomised, Placebo-Controlled Study of the AKT Inhibitor AZD5363 in Combination with Paclitaxel in Triple-Negative Advanced or Metastatic Breast Cancer.
UROPANC
Early detection of pancreatic ductal adenocarcinoma (PDAC) using a panel of biomarkers.
BARBICAN
A randomised, open-label phase II study to determine the contribution of ipatasertib to neoadjuvant chemotherapy plus atezolizumab in women with triple-negative breast cancer
Closed
ABACUS
A phase II study investigating preoperative MPDL3280A in operable transitional cell carcinoma of the bladder.
ARB
Phase II window of opportunity study of short-term preoperative treatment with enzalutamide (alone or in combination with exemestane) in patients with primary breast cancer.
CLEVAR
A clinical enabling study of bone-marrow vascular leak measured by Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) in healthy subjects and patients with Acute Myeloid Leukaemia (AML).
GAMMA
A novel, single arm phase II study for relapsed germ cell tumours with poor prognosis.
HIVEC-II
A phase II, open label, multicentre, randomised controlled trial comparing hyperthermia plus mitomycin to mitomycin alone, in patients with intermediate risk non-muscle invasive bladder cancer.
IMPACT
IMaging pilot study of the αvβ6 integrin radiotracer [18F]-A20FMDV2 in PAtients with solid Cancer Types.
MANTA
A randomized Phase II study of Fulvestrant in combination with the dual mTOR inhibitor AZD2014 or Everolimus or Fulvestrant alone in Estrogen receptor-positive advanced or metastatic breast cancer.
PEBBLE
A phase II study investigating preoperative bintrafusp alfa in operable urothelial carcinoma of the bladder.
PINBALL
A Phase II Pilot Trial Of Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and the Addition Of Paricalcitol Upon Disease Progression in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma.
STARPAC
A Phase 1B study repurposing ATRA as stromal targeting agent along with gemcitabine and nab-Paclitaxel for pancreatic cancer.
TORCMEK
A Phase Ib/IIa study of AZD2014 in combination with Selumetinib in patients with advanced cancers.
TRICREST
A phase II, single arm, multicentre trial of triamcinolone with a GnRH analog for castration resistant prostate cancer.